Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CYAN

Cyanotech (CYAN) Stock Price, News & Analysis

Cyanotech logo

About Cyanotech Stock (NASDAQ:CYAN)

Advanced Chart

Key Stats

Today's Range
$0.35
$0.41
50-Day Range
$2.83
$3.26
52-Week Range
$2.37
$6.29
Volume
22,715 shs
Average Volume
3,483 shs
Market Capitalization
$2.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cyanotech Corp. engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.

Receive CYAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyanotech and its competitors with MarketBeat's FREE daily newsletter.

CYAN Stock News Headlines

Q3 2025 Cyanotech Corp Earnings Call
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Headlines

CYAN Stock Analysis - Frequently Asked Questions

Cyanotech Co. (NASDAQ:CYAN) released its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.16) earnings per share for the quarter. The biotechnology company earned $5.85 million during the quarter. Cyanotech had a negative net margin of 19.50% and a negative trailing twelve-month return on equity of 44.71%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyanotech investors own include AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Allena Pharmaceuticals (ALNA), Clarivate (CCC), Karyopharm Therapeutics (KPTI) and Madrigal Pharmaceuticals (MDGL).

Company Calendar

Last Earnings
11/12/2024
Today
5/13/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medicinals & botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:CYAN
Employees
95
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,270,000.00
Pretax Margin
-19.48%

Debt

Sales & Book Value

Annual Sales
$23.07 million
Price / Cash Flow
N/A
Book Value
$1.33 per share
Price / Book
0.28

Miscellaneous

Free Float
5,074,000
Market Cap
$2.68 million
Optionable
Not Optionable
Beta
-0.11
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:CYAN) was last updated on 5/13/2025 by MarketBeat.com Staff
From Our Partners